The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals - Trial NCT06419686
Access comprehensive clinical trial information for NCT06419686 through Pure Global AI's free database. This Phase 1 trial is sponsored by University Hospital, Gentofte, Copenhagen and is currently Recruiting. The study focuses on Effect of iv Administration of GIP and Alanine. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Gentofte, Copenhagen
Timeline & Enrollment
Phase 1
Jan 01, 2024
Jul 01, 2024
Primary Outcome
Plasma concentrations of Glucagon,Plasma concentrations of Glucagon
Summary
The study is a randomised, double-blinded, placebo-controlled, crossover study enrolling 10
 healthy male participants. Each participant will undergo four separate study days in
 randomised order. Each study day encompasses a continous 90-minute i.v. infusion with either
 placebo, glucose-dependent insulinotropic polypeptide (GIP), alanine or GIP + alanine.
 
 The primary objective of the study is to find out whether intravenous administration of the
 naturally occuring gut hormone GIP and the amino acid alanine, separately and combined,
 results in additive or synergistic glucagonotropic effects during euglycaemic conditions in
 healthy participants. Secondary objectives are to disclose the effect of the abovementioned
 interventions on insulin secretion and circulating levels of total and individual amino
 acids.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06419686
Non-Device Trial